Evidence map›Paper›PMID 37724675›Full record

ReviewCurrent drug research reviews2024

Multiple Sclerosis: New Insights into Molecular Pathogenesis and Novel Platforms for Disease Treatment.

Majid Dejbakht, Morteza Akhzari, Sajad Jalili, Fouziyeh Faraji, Mahdi Barazesh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug research reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Majid DejbakhtDepartment of Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran.
Morteza AkhzariSchool of Nursing, Larestan University of Medical Sciences, Larestan, Iran.
Sajad JaliliDepartment of Orthopedics, School of Medicine, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
Fouziyeh FarajiDepartment of Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran.
Mahdi BarazeshDepartment of Biotechnology, Cellular and Molecular Research Center, School of Paramedical, Gerash University of Medical Sciences, Gerash, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS), a chronic inflammatory disorder, affects the central nervous system

aimsThis review provides a comprehensive insight into MS with a focus on its pathogenesis and recent advances in diagnostic methods and its present and upcoming treatment modalities.

conclusionMS therapy alters quickly as research findings and therapeutic options surrounding MS expand. McDonald's guidelines have created different criteria for MS diagnosis. In recent years, ever-growing interest in the development of PAD inhibitors has led to the generation of many reversible and irreversible PAD inhibitors against the disease with satisfactory therapeutic outcomes.

Indexed as

Multiple SclerosisAnimalsHumansMyelin Basic ProteinProtein-Arginine Deiminase Type 2Myelin Basic ProteinProtein-Arginine Deiminase Type 2Autoimmune attackgenetic factorsmultiple sclerosismyelin basic proteinpeptidyl arginine deaminasetherapeutic drugsvisual symptoms.

Identifiers

PMID37724675

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.